Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054]

De Angelis, C;Bruzzese, D;Bernardo, A;Baldini, E;Leo, L;Fabi, A;Gamucci, T;De Placido, P;Poggio, F;Russo, S;Forestieri, V;Lauria, R;De Santo, I;Caputo, R;Cianniello, D;Michelotti, A;Del Mastro, L;De Laurentiis, M;Giuliano, M;De Placido, S;Arpino, G

2021-01-01